ETOILE: Real-World Evidence of 24 Months of Ranibizumab 0.5 mg in Patients with Visual Impairment Due to Diabetic Macular Edema

Real-world outcomes after 36 months treatment with ranibizumab 0.5 mg in patients with visual impairment due to diabetic macular edema (BOREAL-DME)

(2020) Pascale Massin et al.   OPHTHALMIC RESEARCH

LONG-TIME OUTCOME IN PATIENTS TREATED WITH RANIBIZUMAB FOR DIABETIC MACULAR EDEMA

(2018) David Epstein et al.   RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES

Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting

(2018) Anne-Laurence Best et al.   Journal of Ophthalmology

Pharmacological Management of Diabetic Macular Edema in Real-Life Observational Studies

(2018) Laurent Kodjikian et al.   Biomed Research International

Intravitreal Ranibizumab Therapy for Diabetic Macular Edema in Routine Practice: Two-Year Real-Life Data from a Non-interventional, Multicenter Study in Germany

(2018) Focke Ziemssen et al.   Diabetes Therapy

The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group, Report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema

(2016) Catherine Egan et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Outcomes after a 1-Year Treatment with Ranibizumab for Diabetic Macular Edema in a Clinical Setting

(2016) Linda Hrarat et al.   OPHTHALMOLOGICA

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study

(2015) Christian Prünte et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Predictors of Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Ranibizumab

(2015) Raafay Sophie et al.   OPHTHALMOLOGY

Three-Year Outcomes of Individualized Ranibizumab Treatment in Patients with Diabetic Macular Edema

(2014) Ursula Schmidt-Erfurth et al.   OPHTHALMOLOGY

Global Prevalence and Major Risk Factors of Diabetic Retinopathy

(2012) J. W. Y. Yau et al.   DIABETES CARE

Ranibizumab for Diabetic Macular Edema

(2012) Quan Dong Nguyen et al.   OPHTHALMOLOGY

Expanded 2-Year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema

(2011) Michael J. Elman et al.   OPHTHALMOLOGY

The RESTORE Study

(2011) Paul Mitchell et al.   OPHTHALMOLOGY

Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study): A 12-month, randomized, controlled, double-masked, multicenter phase II study

(2010) P. Massin et al.   DIABETES CARE

Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study

(2010) Quan Dong Nguyen et al.   OPHTHALMOLOGY

Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema

(2010) Michael J. Elman et al.   OPHTHALMOLOGY

Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study

(2009) Quan Dong Nguyen et al.   OPHTHALMOLOGY

The 25-Year Incidence of Visual Impairment in Type 1 Diabetes Mellitus

(2009) Ronald Klein et al.   OPHTHALMOLOGY